Email updates

Keep up to date with the latest news and content from Cardiovascular Diabetology and BioMed Central.

Open Access Highly Accessed Original investigation

N-Acetylcysteine prevents congenital heart defects induced by pregestational diabetes

Hoda Moazzen1, Xiangru Lu1, Noelle L Ma1, Thomas J Velenosi1, Brad L Urquhart123, Lambertus J Wisse4, Adriana C Gittenberger-de Groot5 and Qingping Feng123*

  • * Corresponding author: Qingping Feng qfeng@uwo.ca

  • † Equal contributors

Author Affiliations

1 Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A 5C1, Canada

2 Department of Medicine, London, Ontario, Canada

3 Lawson Health Research Institute, London, Ontario, Canada

4 Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands

5 Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

For all author emails, please log on.

Cardiovascular Diabetology 2014, 13:46  doi:10.1186/1475-2840-13-46

Published: 18 February 2014

Abstract

Background

Pregestational diabetes is a major risk factor of congenital heart defects (CHDs). Glutathione is depleted and reactive oxygen species (ROS) production is elevated in diabetes. In the present study, we aimed to examine whether treatment with N-acetylcysteine (NAC), which increases glutathione synthesis and inhibits ROS production, prevents CHDs induced by pregestational diabetes.

Methods

Female mice were treated with streptozotocin (STZ) to induce pregestational diabetes prior to breeding with normal males to produce offspring. Some diabetic mice were treated with N-acetylcysteine (NAC) in drinking water from E0.5 to the end of gestation or harvesting of the embryos. CHDs were identified by histology. ROS levels, cell proliferation and gene expression in the fetal heart were analyzed.

Results

Our data show that pregestational diabetes resulted in CHDs in 58% of the offspring, including ventricular septal defect (VSD), atrial septal defect (ASD), atrioventricular septal defects (AVSD), transposition of great arteries (TGA), double outlet right ventricle (DORV) and tetralogy of Fallot (TOF). Treatment with NAC in drinking water in pregestational diabetic mice completely eliminated the incidence of AVSD, TGA, TOF and significantly diminished the incidence of ASD and VSD. Furthermore, pregestational diabetes increased ROS, impaired cell proliferation, and altered Gata4, Gata5 and Vegf-a expression in the fetal heart of diabetic offspring, which were all prevented by NAC treatment.

Conclusions

Treatment with NAC increases GSH levels, decreases ROS levels in the fetal heart and prevents the development of CHDs in the offspring of pregestational diabetes. Our study suggests that NAC may have therapeutic potential in the prevention of CHDs induced by pregestational diabetes.

Keywords:
Pregestational diabetes; Congenital heart defects; N-acetylcysteine; Glutathione; Reactive oxygen species